Skip to main content
Top
Published in: Critical Care 2/2012

Open Access 01-04-2012 | Research

Decreased plasma concentrations of apolipoprotein M in sepsis and systemic inflammatory response syndromes

Authors: Sunil B Kumaraswamy, Adam Linder, Per Åkesson, Björn Dahlbäck

Published in: Critical Care | Issue 2/2012

Login to get access

Abstract

Introduction

Apolipoprotein M (apoM) is present in 5% of high-density lipoprotein (HDL) particles in plasma. It is a carrier of sphingosine-1-phosphate (S1P), which is important for vascular barrier protection. The aim was to determine the plasma concentrations of apoM during sepsis and systemic inflammatory response syndrome (SIRS) and correlate them to levels of apolipoprotein A-I (apoA1), apolipoprotein B (apoB), HDL-, and low-density lipoprotein (LDL)-cholesterol.

Methods

Plasma samples from patients with (1), severe sepsis with shock (n = 26); (2), severe sepsis without shock (n = 44); (3), sepsis (n = 100); (4), infections without SIRS (n = 43); and (5) SIRS without infection (n = 20) were analyzed. The concentrations of apoM, apoA1, and apoB were measured with enzyme-linked immunosorbent assays (ELISAs). Total, HDL-, and LDL-cholesterol concentrations were measured with a commercial HDL/LDL cholesterol test.

Results

ApoM concentrations correlated negatively to acute-phase markers. Thus, apoM behaved as a negative acute-phase protein. Decreased values were observed in all patient groups (P < 0.0001), with the most drastic decreases observed in the severely sick patients. ApoM levels correlated strongly to those of apoA1, apoB, HDL, and LDL cholesterol. The HDL and LDL cholesterol levels were low in all patient groups, as compared with controls (P < 0.0001), in particular, HDL cholesterol. ApoA1 and apoB concentrations were low only in the more severely affected patients.

Conclusions

During sepsis and SIRS, the plasma concentrations of apoM decrease dramatically, the degree of decrease reflecting the severity of the disease. As a carrier for barrier-protective S1P in HDL, the decrease in apoM could contribute to the increased vascular leakage observed in sepsis and SIRS.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dahlback B, Nielsen LB: Apolipoprotein M affecting lipid metabolism or just catching a ride with lipoproteins in the circulation? Cell Mol Life Sci 2009, 66: 559-564. 10.1007/s00018-009-8764-8CrossRefPubMed Dahlback B, Nielsen LB: Apolipoprotein M affecting lipid metabolism or just catching a ride with lipoproteins in the circulation? Cell Mol Life Sci 2009, 66: 559-564. 10.1007/s00018-009-8764-8CrossRefPubMed
2.
go back to reference Xu N, Dahlback B: A novel human apolipoprotein (apoM). J Biol Chem 1999, 274: 31286-31290. 10.1074/jbc.274.44.31286CrossRefPubMed Xu N, Dahlback B: A novel human apolipoprotein (apoM). J Biol Chem 1999, 274: 31286-31290. 10.1074/jbc.274.44.31286CrossRefPubMed
3.
go back to reference Axler O, Ahnstrom J, Dahlback B: Apolipoprotein M associates to lipoproteins through its retained signal peptide. FEBS Lett 2008, 582: 826-828. 10.1016/j.febslet.2008.02.007CrossRefPubMed Axler O, Ahnstrom J, Dahlback B: Apolipoprotein M associates to lipoproteins through its retained signal peptide. FEBS Lett 2008, 582: 826-828. 10.1016/j.febslet.2008.02.007CrossRefPubMed
4.
go back to reference Christoffersen C, Ahnstrom J, Axler O, Christensen EI, Dahlback B, Nielsen LB: The signal peptide anchors apolipoprotein M in plasma lipoproteins and prevents rapid clearance of apolipoprotein M from plasma. J Biol Chem 2008, 283: 18765-18772. 10.1074/jbc.M800695200CrossRefPubMed Christoffersen C, Ahnstrom J, Axler O, Christensen EI, Dahlback B, Nielsen LB: The signal peptide anchors apolipoprotein M in plasma lipoproteins and prevents rapid clearance of apolipoprotein M from plasma. J Biol Chem 2008, 283: 18765-18772. 10.1074/jbc.M800695200CrossRefPubMed
5.
go back to reference Christoffersen C, Nielsen LB, Axler O, Andersson A, Johnsen AH, Dahlback B: Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res 2006, 47: 1833-1843. 10.1194/jlr.M600055-JLR200CrossRefPubMed Christoffersen C, Nielsen LB, Axler O, Andersson A, Johnsen AH, Dahlback B: Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res 2006, 47: 1833-1843. 10.1194/jlr.M600055-JLR200CrossRefPubMed
6.
go back to reference Axler O, Ahnstrom J, Dahlback B: An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma. J Lipid Res 2007, 48: 1772-1780. 10.1194/jlr.M700113-JLR200CrossRefPubMed Axler O, Ahnstrom J, Dahlback B: An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma. J Lipid Res 2007, 48: 1772-1780. 10.1194/jlr.M700113-JLR200CrossRefPubMed
7.
go back to reference Duan J, Dahlback B, Villoutreix BO: Proposed lipocalin fold for apolipoprotein M based on bioinformatics and site-directed mutagenesis. FEBS Lett 2001, 499: 127-132. 10.1016/S0014-5793(01)02544-3CrossRefPubMed Duan J, Dahlback B, Villoutreix BO: Proposed lipocalin fold for apolipoprotein M based on bioinformatics and site-directed mutagenesis. FEBS Lett 2001, 499: 127-132. 10.1016/S0014-5793(01)02544-3CrossRefPubMed
8.
go back to reference Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnstrom J, Sevvana M, Egerer-Sieber C, Muller YA, Hla T, Nielsen LB, Dahlback B: Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci USA 2011, 108: 9613-9618. 10.1073/pnas.1103187108PubMedCentralCrossRefPubMed Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnstrom J, Sevvana M, Egerer-Sieber C, Muller YA, Hla T, Nielsen LB, Dahlback B: Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci USA 2011, 108: 9613-9618. 10.1073/pnas.1103187108PubMedCentralCrossRefPubMed
9.
go back to reference Sevvana M, Ahnstrom J, Egerer-Sieber C, Lange HA, Dahlback B, Muller YA: Serendipitous fatty acid binding reveals the structural determinants for ligand recognition in apolipoprotein M. J Mol Biol 2009, 393: 920-936. 10.1016/j.jmb.2009.08.071CrossRefPubMed Sevvana M, Ahnstrom J, Egerer-Sieber C, Lange HA, Dahlback B, Muller YA: Serendipitous fatty acid binding reveals the structural determinants for ligand recognition in apolipoprotein M. J Mol Biol 2009, 393: 920-936. 10.1016/j.jmb.2009.08.071CrossRefPubMed
10.
go back to reference Blaho VA, Hla T: Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors. Chem Rev 2011, 111: 6299-6320. 10.1021/cr200273uPubMedCentralCrossRefPubMed Blaho VA, Hla T: Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors. Chem Rev 2011, 111: 6299-6320. 10.1021/cr200273uPubMedCentralCrossRefPubMed
11.
go back to reference Brinkmann V: Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 2007, 115: 84-105. 10.1016/j.pharmthera.2007.04.006CrossRefPubMed Brinkmann V: Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 2007, 115: 84-105. 10.1016/j.pharmthera.2007.04.006CrossRefPubMed
12.
go back to reference Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S: Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 2009, 78: 743-768. 10.1146/annurev.biochem.78.072407.103733CrossRefPubMed Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S: Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 2009, 78: 743-768. 10.1146/annurev.biochem.78.072407.103733CrossRefPubMed
14.
go back to reference Feingold KR, Shigenaga JK, Chui LG, Moser A, Khovidhunkit W, Grunfeld C: Infection and inflammation decrease apolipoprotein M expression. Atherosclerosis 2008, 199: 19-26. 10.1016/j.atherosclerosis.2007.10.007CrossRefPubMed Feingold KR, Shigenaga JK, Chui LG, Moser A, Khovidhunkit W, Grunfeld C: Infection and inflammation decrease apolipoprotein M expression. Atherosclerosis 2008, 199: 19-26. 10.1016/j.atherosclerosis.2007.10.007CrossRefPubMed
15.
go back to reference Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340: 448-454. 10.1056/NEJM199902113400607CrossRefPubMed Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340: 448-454. 10.1056/NEJM199902113400607CrossRefPubMed
16.
go back to reference Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C: Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004, 45: 1169-1196. 10.1194/jlr.R300019-JLR200CrossRefPubMed Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C: Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004, 45: 1169-1196. 10.1194/jlr.R300019-JLR200CrossRefPubMed
17.
go back to reference Murch O, Collin M, Hinds CJ, Thiemermann C: Lipoproteins in inflammation and sepsis. I. Basic science. Intensive Care Med 2007, 33: 13-24. 10.1007/s00134-006-0432-yCrossRefPubMed Murch O, Collin M, Hinds CJ, Thiemermann C: Lipoproteins in inflammation and sepsis. I. Basic science. Intensive Care Med 2007, 33: 13-24. 10.1007/s00134-006-0432-yCrossRefPubMed
18.
go back to reference Wendel M, Paul R, Heller AR: Lipoproteins in inflammation and sepsis. II. Clinical aspects. Intensive Care Med 2007, 33: 25-35. 10.1007/s00134-006-0433-xCrossRefPubMed Wendel M, Paul R, Heller AR: Lipoproteins in inflammation and sepsis. II. Clinical aspects. Intensive Care Med 2007, 33: 25-35. 10.1007/s00134-006-0433-xCrossRefPubMed
19.
go back to reference Kontush A, Chapman MJ: Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006, 58: 342-374. 10.1124/pr.58.3.1CrossRefPubMed Kontush A, Chapman MJ: Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006, 58: 342-374. 10.1124/pr.58.3.1CrossRefPubMed
20.
go back to reference Kitchens RL, Thompson PA, Munford RS, O'Keefe GE: Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins. J Lipid Res 2003, 44: 2339-2348. 10.1194/jlr.M300228-JLR200CrossRefPubMed Kitchens RL, Thompson PA, Munford RS, O'Keefe GE: Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins. J Lipid Res 2003, 44: 2339-2348. 10.1194/jlr.M300228-JLR200CrossRefPubMed
21.
go back to reference Levels JH, Lemaire LC, van den Ende AE, van Deventer SJ, van Lanschot JJ: Lipid composition and lipopolysaccharide binding capacity of lipoproteins in plasma and lymph of patients with systemic inflammatory response syndrome and multiple organ failure. Crit Care Med 2003, 31: 1647-1653. 10.1097/01.CCM.0000063260.07222.76CrossRefPubMed Levels JH, Lemaire LC, van den Ende AE, van Deventer SJ, van Lanschot JJ: Lipid composition and lipopolysaccharide binding capacity of lipoproteins in plasma and lymph of patients with systemic inflammatory response syndrome and multiple organ failure. Crit Care Med 2003, 31: 1647-1653. 10.1097/01.CCM.0000063260.07222.76CrossRefPubMed
22.
go back to reference Navab M, Reddy ST, Van Lenten BJ, Fogelman AM: HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011, 8: 222-232. 10.1038/nrcardio.2010.222CrossRefPubMed Navab M, Reddy ST, Van Lenten BJ, Fogelman AM: HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011, 8: 222-232. 10.1038/nrcardio.2010.222CrossRefPubMed
23.
24.
go back to reference Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008, 34: 17-60. 10.1007/s00134-007-0934-2PubMedCentralCrossRefPubMed Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008, 34: 17-60. 10.1007/s00134-007-0934-2PubMedCentralCrossRefPubMed
25.
go back to reference Annane D, Bellissant E, Cavaillon JM: Septic shock. Lancet 2005, 365: 63-78. 10.1016/S0140-6736(04)17667-8CrossRefPubMed Annane D, Bellissant E, Cavaillon JM: Septic shock. Lancet 2005, 365: 63-78. 10.1016/S0140-6736(04)17667-8CrossRefPubMed
26.
go back to reference Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348: 138-150. 10.1056/NEJMra021333CrossRefPubMed Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348: 138-150. 10.1056/NEJMra021333CrossRefPubMed
27.
go back to reference Barlage S, Gnewuch C, Liebisch G, Wolf Z, Audebert FX, Gluck T, Frohlich D, Kramer BK, Rothe G, Schmitz G: Changes in HDL-associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation. Intensive Care Med 2009, 35: 1877-1885. 10.1007/s00134-009-1609-yCrossRefPubMed Barlage S, Gnewuch C, Liebisch G, Wolf Z, Audebert FX, Gluck T, Frohlich D, Kramer BK, Rothe G, Schmitz G: Changes in HDL-associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation. Intensive Care Med 2009, 35: 1877-1885. 10.1007/s00134-009-1609-yCrossRefPubMed
28.
go back to reference Berbee JF, van der Hoogt CC, de Haas CJ, van Kessel KP, Dallinga-Thie GM, Romijn JA, Havekes LM, van Leeuwen HJ, Rensen PC: Plasma apolipoprotein CI correlates with increased survival in patients with severe sepsis. Intensive Care Med 2008, 34: 907-911. 10.1007/s00134-008-1006-yCrossRefPubMed Berbee JF, van der Hoogt CC, de Haas CJ, van Kessel KP, Dallinga-Thie GM, Romijn JA, Havekes LM, van Leeuwen HJ, Rensen PC: Plasma apolipoprotein CI correlates with increased survival in patients with severe sepsis. Intensive Care Med 2008, 34: 907-911. 10.1007/s00134-008-1006-yCrossRefPubMed
29.
go back to reference Chenaud C, Merlani PG, Roux-Lombard P, Burger D, Harbarth S, Luyasu S, Graf JD, Dayer JM, Ricou B: Low apolipoprotein A-I level at intensive care unit admission and systemic inflammatory response syndrome exacerbation. Crit Care Med 2004, 32: 632-637. 10.1097/01.CCM.0000114820.47460.0ACrossRefPubMed Chenaud C, Merlani PG, Roux-Lombard P, Burger D, Harbarth S, Luyasu S, Graf JD, Dayer JM, Ricou B: Low apolipoprotein A-I level at intensive care unit admission and systemic inflammatory response syndrome exacerbation. Crit Care Med 2004, 32: 632-637. 10.1097/01.CCM.0000114820.47460.0ACrossRefPubMed
30.
go back to reference Chien JY, Jerng JS, Yu CJ, Yang PC: Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med 2005, 33: 1688-1693. 10.1097/01.CCM.0000171183.79525.6BCrossRefPubMed Chien JY, Jerng JS, Yu CJ, Yang PC: Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med 2005, 33: 1688-1693. 10.1097/01.CCM.0000171183.79525.6BCrossRefPubMed
31.
go back to reference Grion CM, Cardoso LT, Perazolo TF, Garcia AS, Barbosa DS, Morimoto HK, Matsuo T, Carrilho AJ: Lipoproteins and CETP levels as risk factors for severe sepsis in hospitalized patients. Eur J Clin Invest 2010, 40: 330-338. 10.1111/j.1365-2362.2010.02269.xCrossRefPubMed Grion CM, Cardoso LT, Perazolo TF, Garcia AS, Barbosa DS, Morimoto HK, Matsuo T, Carrilho AJ: Lipoproteins and CETP levels as risk factors for severe sepsis in hospitalized patients. Eur J Clin Invest 2010, 40: 330-338. 10.1111/j.1365-2362.2010.02269.xCrossRefPubMed
32.
go back to reference Vermont CL, den Brinker M, Kakeci N, de Kleijn ED, de Rijke YB, Joosten KF, de Groot R, Hazelzet JA: Serum lipids and disease severity in children with severe meningococcal sepsis. Crit Care Med 2005, 33: 1610-1615. 10.1097/01.CCM.0000171272.50888.ADCrossRefPubMed Vermont CL, den Brinker M, Kakeci N, de Kleijn ED, de Rijke YB, Joosten KF, de Groot R, Hazelzet JA: Serum lipids and disease severity in children with severe meningococcal sepsis. Crit Care Med 2005, 33: 1610-1615. 10.1097/01.CCM.0000171272.50888.ADCrossRefPubMed
33.
go back to reference Linder A, Christensson B, Herwald H, Bjorck L, Akesson P: Heparin-binding protein: an early marker of circulatory failure in sepsis. Clin Infect Dis 2009, 49: 1044-1050. 10.1086/605563CrossRefPubMed Linder A, Christensson B, Herwald H, Bjorck L, Akesson P: Heparin-binding protein: an early marker of circulatory failure in sepsis. Clin Infect Dis 2009, 49: 1044-1050. 10.1086/605563CrossRefPubMed
34.
go back to reference Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: the ACCP/SCCM Consensus Conference Committee, American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101: 1644-1655. 10.1378/chest.101.6.1644CrossRefPubMed Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: the ACCP/SCCM Consensus Conference Committee, American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101: 1644-1655. 10.1378/chest.101.6.1644CrossRefPubMed
35.
go back to reference Rodriguez C, Gonzalez-Diez M, Badimon L, Martinez-Gonzalez J: Sphingosine-1-phosphate: bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin. Thromb Haemost 2009, 101: 665-673.PubMed Rodriguez C, Gonzalez-Diez M, Badimon L, Martinez-Gonzalez J: Sphingosine-1-phosphate: bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin. Thromb Haemost 2009, 101: 665-673.PubMed
36.
go back to reference Elsoe S, Ahnstrom J, Christoffersen C, Hoofnagle AN, Plomgaard P, Heinecke JW, Binder CJ, Bjorkbacka H, Dahlback B, Nielsen LB: Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL. Atherosclerosis 2012, 221: 91-7. 10.1016/j.atherosclerosis.2011.11.031CrossRefPubMed Elsoe S, Ahnstrom J, Christoffersen C, Hoofnagle AN, Plomgaard P, Heinecke JW, Binder CJ, Bjorkbacka H, Dahlback B, Nielsen LB: Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL. Atherosclerosis 2012, 221: 91-7. 10.1016/j.atherosclerosis.2011.11.031CrossRefPubMed
37.
go back to reference Mosialou I, Krasagakis K, Kardassis D: Opposite regulation of the human apolipoprotein M gene by hepatocyte nuclear factor 1 and Jun transcription factors. J Biol Chem 2011, 286: 17259-17269. 10.1074/jbc.M110.200659PubMedCentralCrossRefPubMed Mosialou I, Krasagakis K, Kardassis D: Opposite regulation of the human apolipoprotein M gene by hepatocyte nuclear factor 1 and Jun transcription factors. J Biol Chem 2011, 286: 17259-17269. 10.1074/jbc.M110.200659PubMedCentralCrossRefPubMed
38.
go back to reference Mosialou I, Zannis VI, Kardassis D: Regulation of human apolipoprotein M gene expression by orphan and ligand-dependent nuclear receptors. J Biol Chem 2010, 285: 30719-30730. 10.1074/jbc.M110.131771PubMedCentralCrossRefPubMed Mosialou I, Zannis VI, Kardassis D: Regulation of human apolipoprotein M gene expression by orphan and ligand-dependent nuclear receptors. J Biol Chem 2010, 285: 30719-30730. 10.1074/jbc.M110.131771PubMedCentralCrossRefPubMed
39.
go back to reference Richter S, Shih DQ, Pearson ER, Wolfrum C, Fajans SS, Hattersley AT, Stoffel M: Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes 2003, 52: 2989-2995. 10.2337/diabetes.52.12.2989CrossRefPubMed Richter S, Shih DQ, Pearson ER, Wolfrum C, Fajans SS, Hattersley AT, Stoffel M: Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes 2003, 52: 2989-2995. 10.2337/diabetes.52.12.2989CrossRefPubMed
40.
go back to reference Memon RA, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR: In vivo and in vitro regulation of sterol 27-hydroxylase in the liver during the acute phase response: potential role of hepatocyte nuclear factor-1. J Biol Chem 2001, 276: 30118-30126. 10.1074/jbc.M102516200CrossRefPubMed Memon RA, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR: In vivo and in vitro regulation of sterol 27-hydroxylase in the liver during the acute phase response: potential role of hepatocyte nuclear factor-1. J Biol Chem 2001, 276: 30118-30126. 10.1074/jbc.M102516200CrossRefPubMed
Metadata
Title
Decreased plasma concentrations of apolipoprotein M in sepsis and systemic inflammatory response syndromes
Authors
Sunil B Kumaraswamy
Adam Linder
Per Åkesson
Björn Dahlbäck
Publication date
01-04-2012
Publisher
BioMed Central
Published in
Critical Care / Issue 2/2012
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc11305

Other articles of this Issue 2/2012

Critical Care 2/2012 Go to the issue